Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(6):822–828. doi: 10.1038/bjc.1997.147

Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.

A M Di Massimo 1, M Di Loreto 1, A Pacilli 1, G Raucci 1, L D'Alatri 1, A Mele 1, A Bolognesi 1, L Polito 1, F Stirpe 1, R De Santis 1
PMCID: PMC2063398  PMID: 9062402

Abstract

The present paper describes two immunoconjugates consisting of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), named Mint5, covalently linked to the type 1 ribosome-inactivating proteins (RIPs) ocymoidine (Ocy) and pyramidatine (Pyra) from Saponaria ocymoides and Vaccaria pyramidata respectively. Both antibody and toxins are shown to retain their respective biological properties upon chemical conjugation. The immunoconjugates exert specific inhibition of EGFR expressing target cell proliferation and protein synthesis in in vitro assays and also inhibit the growth of grafted human tumour cells in nude mice.

Full text

PDF
823

Images in this article

824Figure 2
on p.824

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbieri L., Battelli M. G., Stirpe F. Ribosome-inactivating proteins from plants. Biochim Biophys Acta. 1993 Dec 21;1154(3-4):237–282. doi: 10.1016/0304-4157(93)90002-6. [DOI] [PubMed] [Google Scholar]
  2. Baselga J., Norton L., Masui H., Pandiella A., Coplan K., Miller W. H., Jr, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993 Aug 18;85(16):1327–1333. doi: 10.1093/jnci/85.16.1327. [DOI] [PubMed] [Google Scholar]
  3. Bolognesi A., Barbieri L., Abbondanza A., Falasca A. I., Carnicelli D., Battelli M. G., Stirpe F. Purification and properties of new ribosome-inactivating proteins with RNA N-glycosidase activity. Biochim Biophys Acta. 1990 Nov 30;1087(3):293–302. doi: 10.1016/0167-4781(90)90002-j. [DOI] [PubMed] [Google Scholar]
  4. Bolognesi A., Olivieri F., Battelli M. G., Barbieri L., Falasca A. I., Parente A., Del Vecchio Blanco F., Stirpe F. Ribosome-inactivating proteins (RNA N-glycosidases) from the seeds of Saponaria ocymoides and Vaccaria pyramidata. Eur J Biochem. 1995 Mar 15;228(3):935–940. doi: 10.1111/j.1432-1033.1995.tb20343.x. [DOI] [PubMed] [Google Scholar]
  5. Endo Y., Huber P. W., Wool I. G. The ribonuclease activity of the cytotoxin alpha-sarcin. The characteristics of the enzymatic activity of alpha-sarcin with ribosomes and ribonucleic acids as substrates. J Biol Chem. 1983 Feb 25;258(4):2662–2667. [PubMed] [Google Scholar]
  6. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem. 1987 Jun 15;262(17):8128–8130. [PubMed] [Google Scholar]
  7. Endo Y., Tsurugi K. The RNA N-glycosidase activity of ricin A-chain. The characteristics of the enzymatic activity of ricin A-chain with ribosomes and with rRNA. J Biol Chem. 1988 Jun 25;263(18):8735–8739. [PubMed] [Google Scholar]
  8. Ennis B. W., Lippman M. E., Dickson R. B. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 1991;9(5):553–562. doi: 10.3109/07357909109018953. [DOI] [PubMed] [Google Scholar]
  9. Fox S. B., Smith K., Hollyer J., Greenall M., Hastrich D., Harris A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat. 1994 Jan;29(1):41–49. doi: 10.1007/BF00666180. [DOI] [PubMed] [Google Scholar]
  10. Frankel A. E., Tagge E. P., Willingham M. C. Clinical trials of targeted toxins. Semin Cancer Biol. 1995 Oct;6(5):307–317. doi: 10.1006/scbi.1995.0039. [DOI] [PubMed] [Google Scholar]
  11. Friedman P. N., Chace D. F., Trail P. A., Siegall C. B. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J Immunol. 1993 Apr 1;150(7):3054–3061. [PubMed] [Google Scholar]
  12. Lappi D. A., Baird A. Mitotoxins: growth factor-targeted cytotoxic molecules. Prog Growth Factor Res. 1990;2(4):223–236. doi: 10.1016/0955-2235(90)90020-k. [DOI] [PubMed] [Google Scholar]
  13. Lorimer I. A., Wikstrand C. J., Batra S. K., Bigner D. D., Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res. 1995 Aug;1(8):859–864. [PubMed] [Google Scholar]
  14. Masui H., Kamrath H., Apell G., Houston L. L., Mendelsohn J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res. 1989 Jul 1;49(13):3482–3488. [PubMed] [Google Scholar]
  15. Ozawa S., Ueda M., Ando N., Abe O., Minoshima S., Shimizu N. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer. 1989 Jan 15;43(1):152–157. doi: 10.1002/ijc.2910430128. [DOI] [PubMed] [Google Scholar]
  16. Stirpe F., Bailey S., Miller S. P., Bodley J. W. Modification of ribosomal RNA by ribosome-inactivating proteins from plants. Nucleic Acids Res. 1988 Feb 25;16(4):1349–1357. doi: 10.1093/nar/16.4.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Strocchi P., Barbieri L., Stirpe F. Immunological properties of ribosome-inactivating proteins and a saporin immunotoxin. J Immunol Methods. 1992 Oct 19;155(1):57–63. doi: 10.1016/0022-1759(92)90271-t. [DOI] [PubMed] [Google Scholar]
  18. Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988 Nov 15;48(22):6396–6403. [PubMed] [Google Scholar]
  19. Tosi E., Valota O., Negri D. R., Adobati E., Mazzoni A., Meazza R., Ferrini S., Colnaghi M. I., Canevari S. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int J Cancer. 1995 Sep 4;62(5):643–650. doi: 10.1002/ijc.2910620525. [DOI] [PubMed] [Google Scholar]
  20. Wawrzynczak E. J. Systemic immunotoxin therapy of cancer: advances and prospects. Br J Cancer. 1991 Oct;64(4):624–630. doi: 10.1038/bjc.1991.374. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES